Erratum
Junxia Zhang(Shaoyang University), Sheryl R. Simon, Elisa Melucci, Christian Delloye, Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Kathryn Effendi(Keio University), Peng Zhao, M. Mottolese, Letizia Perracchio, Athanassios P. Kyritsis, Andreas Fotopoulos, Giulio Metro(University of Perugia), Amy Schmotzer, Lei Shi, Frédéric Lecouvet(Cliniques Universitaires Saint-Luc), Olivier Cartiaux, Alok A. Khorana(Cleveland Clinic), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Chunsheng Kang(Tianjin Medical University General Hospital), Denis Dufrane(Novadip (Belgium)), Alessandra Fabi(Agostino Gemelli University Polyclinic), Peter Reichardt(Helios Hospital Berlin-Buch), Michelle Shayne(University of Rochester), Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Milind Javle(The University of Texas MD Anderson Cancer Center), Michele Stanislaw Milella(University of Verona), Pierre‐Louis Docquier(Cliniques Universitaires Saint-Luc), Chrissa Sioka, Charles A. Laughton, J. Bonneterre, Shelly S. Lo, P. Vici, B. Antoniani, I. Sperduti, Michiie Sakamoto(Keio University), Ning Liu, Hong Wang(Beijing Institute of Technology), Jihong Zhang(Kunming University of Science and Technology), F. Cognetti(Sapienza University of Rome), A. Di Benedetto, Alexander Hantel, Christine Galant, Jimmy Hwang, Malcolm F. G. Stevens(Cardiff University), Charles Ferté(CentraleSupélec), Ramesh K. Ramanathan(Ironwood Pharmaceuticals (United States)), Yongping You(Jiangsu Provincial Hospital of Traditional Chinese Medicine), Antoine Adenis(Centre Oscar Lambret), Tracey D. Bradshaw(University of Nottingham)
Cited by 0
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
|Clinical Cancer Research|2016|1.2k